Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence.

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Abstract Text:

David Rp Guay,

Trospium chloride is a quaternary ammonium compound, which is a competitive antagonist at muscarinic cholinergic receptors. Preclinical studies using porcine and human detrusor muscle strips demonstrated that trospium chloride was many-fold more potent than oxybutynin and tolterodine in inhibiting contractile responses to carbachol and electrical stimulation. The drug is poorly bioavailable orally (< 10%) and food reduces absorption by 70%- 80%. It is predominantly eliminated renally as unchanged compound. Trospium chloride, dosed 20 mg twice daily, is significantly superior to placebo in improving cystometric parameters, reducing urinary frequency, reducing incontinence episodes, and increasing urine volume per micturition. In active-controlled trials, trospium chloride was at least equivalent to immediate-release formulations of oxybutynin and tolterodine in efficacy and tolerability. The most problematic adverse effects of trospium chloride are the anticholinergic effects of dry mouth and constipation. Comparative efficacy/tolerability data with long-acting formulations of oxybutynin and tolterodine as well as other anticholinergics such as solifenacin and darifenacin are not available. On the basis of available data, trospium chloride does not appear to be a substantial advance upon existing anticholinergics in the management of urge urinary incontinence.

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Publishing Authors By Initials

DR Guay,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Therapeutics and clinical risk management

VOLUME: 1

Page Numbers: 157-67

Journal Abbreviation:

ISSN: 1176-6336

DAY: 24

MONTH: Jun

YEAR: 2005

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101253281

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence.

AFFILIATION: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota Minneapolis, MN, USA.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ther Clin Risk Manag

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence Related Publications

• A scripted activity study of the impact of protective advice on personal exposure to ultra-fine and fine particulate matter and volatile organic compounds.
• Acute nicotine effects on sexual function in men.
• Adaptive control for a class of second-order nonlinear systems with unknown input nonlinearities.
• Adverse consequences of capsaicin exposure in health care workers.
• Are there alternatives to the use of quinine to treat nocturnal leg cramps?
• Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors.
• Contemporary management of uncomplicated urinary tract infections.
• First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease/Prudence est mere de surete: evaluer le ratio benefice/risque de l'anesthesie regionale chez les patients porteurs de pathologie ne
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Geriatric pharmacotherapy updates.
• Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
• High optical transparency and good adhesion of diamond films deposited on fused silica windows with a surface-wave sustained plasma.
• Moxifloxacin in the treatment of skin and skin structure infections.
• Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability.
• Pneumococcal polysaccharide revaccination: immunoglobulin g seroconversion, persistence, and safety in frail, chronically ill older subjects.
• Radiographic assessment of asymmetry of the mandible.
• Regional anesthesia for carotid surgery.
• The role dentists can play in mass casualty and disaster events.
• Topical clindamycin in the management of acne vulgaris.
• Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence.
• Update on clindamycin in the management of bacterial, fungal and protozoal infections.
• [Impact of moment of disclosure of a sexual assault on certain affective and relational aspects of adult victims.]
• [Not Available.]
• [Not Available.]
• [Taenia infestation: new method of treatment.]
• [The social worker and family caregivers.]